Home › Research › What the research found › Every row
Every row of the evidence table
One row per finding: what was tested, which way the result went, and how the study was built. The answer by area, and where the studies disagree, are on the main page.
Every row
Filter
Showing 2 of 382 rows for Cholinesterase inhibitor / memantine. One row per study per exposure: a study that tested two different things appears twice, once for each.
Scroll the table sideways to see every column.
| Exposure | Question | Direction | Outcome measured | Design | People | Effect size, as the source reported it | Source |
|---|---|---|---|---|---|---|---|
| Cholinesterase inhibitor / memantine Medicines | Treatment |
Benefit
whyObservational: 80% of residents were on no anti-dementia drug, so who gets prescribed and who does not may itself track prognosis. |
All-cause mortality | cohort study | 25,358 | Adjusted hazard ratios for mortality vs no anti-dementia drug: "HR: 0.826, 95%CI 0.769 to 0.888 for AChEI; 0.857, 95%CI 0.795 to 0.923 for memantine; 0.742, 95%CI 0.640 to 0.861 for AChEI plus memantine" |
Alzheimer's Research & Therapy
2024 ✓ Peer-reviewed PMID 38812028 |
| Cholinesterase inhibitor / memantine Medicines | Treatment |
Benefit
whyCholinesterase inhibitors, not memantine: -0.39 MMSE points a year against -2.50 with no treatment. The mortality benefit held only in the first year. Registry data with weighting, not a trial. |
MMSE decline per year; mortality | cohort study | 1,095 | MMSE change: -0.39 points/year (95% CI -0.96 to 0.18) with cholinesterase inhibitors vs -2.49 (-4.02 to -0.97) with memantine and -2.50 (-4.28 to -0.73) with non-use. Mortality in the first year after diagnosis: adjusted HR 0.66 (95% CI 0.46 to 0.94) |
Alzheimer's & Dementia
2024 ✓ Peer-reviewed PMID 39177108 |
Last updated